Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 2Neuroblastoma 2Meningioma 2Medulloblastoma 2Malnutrition 2Lung Neoplasms 1Liver Neoplasms 1Liver Failure 1Hyperphagia 1Hyperinsulinism 1Hematologic Neoplasms 1Fibrosis 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × Amino Acids × Clear all
NCT03908255 2022-01-28

BCAA in HCC

Louisiana State University Health Sciences Center in New Orleans

Phase 2 Withdrawn
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Liver Failure, Malnutrition

Data powered by HemOnc (CC BY 4.0) Colophon âš¡